Titration schedule planner

GLP-1 Titration Schedule Planner

Turns a start date into the actual weeks of your dose ladder, taking every step and its duration from the drug's own FDA prescribing information. Pick the medication, set the date, and say where you are now if you want only what is left rather than the whole climb.

MedicationStart date

Already partway up — show me only what is left

Important: How you tolerate it is what your prescriber will adjust against. What you see is the label's standard protocol, and no dose on it moves without clinical guidance. Where a step is genuinely intolerable, speak to them before the next increase rather than after it.

Wegovy (semaglutide 2.4 mg) — titration calendar

Maintenance dose

2.4 mg weekly

Weeks to maintenance

16 weeks

First maintenance dose

Jan 20, 2027

Week	Date range	Dose	Pen color	Notes
1	Sep 30, 2026 — Oct 6, 2026	0.25 mg weekly	Light blue	Starting dose — dose-escalation phase
2	Oct 7, 2026 — Oct 13, 2026	0.25 mg weekly	Light blue	Starting dose — dose-escalation phase
3	Oct 14, 2026 — Oct 20, 2026	0.25 mg weekly	Light blue	Starting dose — dose-escalation phase
4	Oct 21, 2026 — Oct 27, 2026	0.25 mg weekly	Light blue	Starting dose — dose-escalation phase
5	Oct 28, 2026 — Nov 3, 2026	0.5 mg weekly	Red-violet
6	Nov 4, 2026 — Nov 10, 2026	0.5 mg weekly	Red-violet
7	Nov 11, 2026 — Nov 17, 2026	0.5 mg weekly	Red-violet
8	Nov 18, 2026 — Nov 24, 2026	0.5 mg weekly	Red-violet
9	Nov 25, 2026 — Dec 1, 2026	1 mg weekly	Yellow
10	Dec 2, 2026 — Dec 8, 2026	1 mg weekly	Yellow
11	Dec 9, 2026 — Dec 15, 2026	1 mg weekly	Yellow
12	Dec 16, 2026 — Dec 22, 2026	1 mg weekly	Yellow
13	Dec 23, 2026 — Dec 29, 2026	1.7 mg weekly	Teal
14	Dec 30, 2026 — Jan 5, 2027	1.7 mg weekly	Teal
15	Jan 6, 2027 — Jan 12, 2027	1.7 mg weekly	Teal
16	Jan 13, 2027 — Jan 19, 2027	1.7 mg weekly	Teal
17	Jan 20, 2027 — Jan 26, 2027	2.4 mg weekly	Dark blue	MAINTENANCEMaintenance dose reached
18	Jan 27, 2027 — Feb 2, 2027	2.4 mg weekly	Dark blue	MAINTENANCEMaintenance dose reached
19	Feb 3, 2027 — Feb 9, 2027	2.4 mg weekly	Dark blue	MAINTENANCEMaintenance dose reached
20	Feb 10, 2027 — Feb 16, 2027	2.4 mg weekly	Dark blue	MAINTENANCEMaintenance dose reached

How the planner works

Nothing here is invented. Every dose, every duration, every pen color is read off the prescribing information for that drug, and all this does is lay the label's own protocol against real dates.

Wegovy (semaglutide) [1]: Four-week steps, five of them, carrying 0.25 mg up to a maintenance dose of 2.4 mg across 16 weeks.
Ozempic (semaglutide) [2]: Four weeks at 0.25 mg to begin, then 0.5 mg, with 1.0 mg and 2.0 mg available above that if needed.
Zepbound / Mounjaro (tirzepatide) [3][4]: Sixteen weeks, rising 2.5 mg at a time every four, from 2.5 mg to a ceiling of 15 mg.
Foundayo (orforglipron) [5]: A tablet taken daily, climbing from 3 mg to a maintenance dose of 36 mg over 12 weeks.

Important warning

How you tolerate it is what your prescriber will adjust against. What you see is the label's standard protocol, and no dose on it should move without clinical guidance. Where a rung is genuinely intolerable, speak to your prescriber before your next scheduled increase — they may recommend staying at the current dose for additional weeks or reducing the dose.

What this planner does NOT do

It gives no medical advice and replaces no conversation with your prescriber.
It cannot judge how you are coping. Every label carries “as tolerated” language, and applying that is your prescriber's job rather than this page's.
It writes no prescription and places no order.
It records nothing you actually did. What you see is the plan, for reference.

Important disclaimer

Educational only. Neither medical advice nor a prescription. What it lays out is the standard protocol from each label, and yours may well run differently once your clinical response, your tolerance and your prescriber's judgment are in play. No dose changes without talking to them first.

References

1.Novo Nordisk. Wegovy (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1: Recommended Dosage. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
2.Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s020lbl.pdf
3.Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf
4.Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use — Prescribing Information. Section 2.1. FDA / Drugs@FDA. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866Orig1s000lbl.pdf
5.Eli Lilly and Company. Foundayo (orforglipron) tablets — Prescribing Information. FDA / Drugs@FDA. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218226s000lbl.pdf

Related tools and research

GLP-1 Dose Plotter — visualize your dose history over time
GLP-1 Unit Converter — convert between mg, mL, and units
GLP-1 Missed Dose Guide — a dose missed partway up the ladder
GLP-1 Weight Loss Calculator — week-by-week weight loss projections
Switching between GLP-1 medications — what changing drug does to the ladder
Semaglutide side effects: what to expect — the gut effects that set how fast you can climb
Side-effect timeline tool — when each side effect peaks and resolves, by drug and week. Slower titration shifts the peak; this tool shows what you avoid.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0